Public Employees Retirement Association of Colorado Purchases New Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Public Employees Retirement Association of Colorado purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 17,217 shares of the company’s stock, valued at approximately $129,000.

Several other hedge funds have also recently bought and sold shares of the stock. Dimensional Fund Advisors LP lifted its holdings in Recursion Pharmaceuticals by 152.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,137,110 shares of the company’s stock worth $21,079,000 after purchasing an additional 1,291,946 shares during the last quarter. UBS Group AG boosted its position in shares of Recursion Pharmaceuticals by 101.9% in the fourth quarter. UBS Group AG now owns 691,911 shares of the company’s stock valued at $6,822,000 after acquiring an additional 349,232 shares during the period. Nomura Asset Management Co. Ltd. acquired a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $457,000. Lingotto Investment Management LLP increased its position in Recursion Pharmaceuticals by 141.9% during the fourth quarter. Lingotto Investment Management LLP now owns 1,875,077 shares of the company’s stock worth $18,488,000 after acquiring an additional 1,100,000 shares during the period. Finally, CIBC Private Wealth Group LLC acquired a new stake in Recursion Pharmaceuticals in the 4th quarter worth about $1,348,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Trading Down 2.6 %

Shares of RXRX stock opened at $6.98 on Monday. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.97 and a fifty-two week high of $15.74. The stock’s fifty day moving average price is $7.03 and its two-hundred day moving average price is $8.19. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07. The company has a market cap of $1.66 billion, a PE ratio of -4.36 and a beta of 0.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.42 million during the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business’s revenue was up 30.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.38) EPS. Equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $7.32, for a total value of $83,792.04. Following the sale, the director now owns 7,167,110 shares in the company, valued at $52,463,245.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $6.17, for a total value of $92,550.00. Following the completion of the transaction, the chief financial officer now owns 1,377,756 shares in the company, valued at approximately $8,500,754.52. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $7.32, for a total transaction of $83,792.04. Following the sale, the director now directly owns 7,167,110 shares in the company, valued at $52,463,245.20. The disclosure for this sale can be found here. Insiders sold a total of 225,682 shares of company stock worth $1,590,044 in the last three months. 15.75% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

RXRX has been the topic of a number of analyst reports. Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Jefferies Financial Group dropped their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. KeyCorp cut their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Finally, Needham & Company LLC decreased their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.